Before deciding to participate in a clinical trial, you should talk to your physician. Clinical trial participants enroll to possibly receive the newest treatment for their conditions, as well as to have additional care and attention from clinical trial staff and to help researchers find better treatments for future patients.
In the United States, clinical trials must meet rigorous standards and be registered with the National Institutes of Health. Registered trials are listed at clinicaltrials.gov as part of a searchable database.
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). Patient participation is up to 18 months.
Participant requirements:
A phase 2, randomized, muticentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic macular edema (DME).
Participant requirements:
A phase 3 multicenter, randomized, double masked, sham-controlled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura (complement c5 inhibitor) in patients with geographic atrophy secondary to age-related macular degeneration. The objective of this study is to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Participant requirements:
This study is focused on understanding how genetics and lifestyle affect Age-related Macular Degeneration. This is not an interventional study; Clover Therapeutics will not draw blood and will not give medication. The researcher is just looking to observe this condition through a health survey and a saliva sample to better understand the disease.
Participant requirements:
This is a Phase 2, double-masked, placebo-controlled, dose range finding study of Danicopan (ALXN2040) in patients with geographic atrophy (GA) secondary to age-related macular degeneration.
Participant requirements:
A phase 3, multicentre, double-masked, randomised study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with Ranibizumab, compared with Ranibizumab alone, in participants with neovascular age-related macular degeneration (NAMD).
Participant requirements:
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). This randomized, partially masked, controlled, phase 2b/3 clinical study will evaluate the efficacy and safety of RGX-314 gene therapy in participants with nAMD. The study will evaluate 2 dose levels of RGX-314 relative to an active comparator.
Participant requirements:
A retrospective registry study to collect real-world data on Yutiq, a fluocinolone acetonide intravitreal implant, for the treatment of chronic non-infectious uveitis affecting the posterior segment. The purpose of the study is to collect data on a cohort of patients treated with fluocinolone acetonide intravitreal inserts for the analysis of efficacy outcomes and adverse events and to determine local or systemic factors which might predict treatment response and identify adverse safety events.
Participant requirements:
A natural history observation and registry study of macular telangiectasia type 2.
Participant requirements:
A randomized, double-masked, 48-week, parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of rg7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naïve diabetic retinopathy. The objective is to assess the effect of RG7774 on the severity of diabetic retinopathy and evaluate the safety and tolerability of RG7774.
Participant requirements:
A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to branch retinal vein occlusion. This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab compared with aflibercept in patients with macular edema due to BRVO up to the primary endpoint at Week 24.
Participant requirements:
A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion. This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab compared with aflibercept in patients with macular edema due to CRVO or HRVO up to the primary endpoint at Week 24.
Participant requirements:
Please fill out the form below, or contact Melinda Yousefi, PhD at research@coloradoretina.com or 719-473-9595 x130 if you want further information regarding our clinical trials.
